Cognitive dysfunction in neuropsychiatric disorders

Selected serotonin receptor subtypes as therapeutic targets

Alvin V Terry, Jerry J. Buccafusco, Christina A Wilson

Research output: Contribution to journalReview article

95 Citations (Scopus)

Abstract

The indolamine, serotonin (5-hydroxytryptamine-5-HT) was identified and initially characterized around the middle of the twentieth century and it is now known to participate in multiple physiologic processes in mammalians. As a neurotransmitter, 5-HT is well documented to play a significant role in the pathophysiology and treatment of a variety of psychiatric disorders including anxiety, depression, and schizophrenia. In addition, there is also some evidence to suggest that 5-HT function in the brain may be important (particularly in the behavioral disturbances) in various forms of dementia including Alzheimer's disease. While 5-HT is undoubtedly involved in cognitive function, its role in specific domains of cognition (attention, learning, and memory, etc.) is poorly understood. This understanding has been impeded to some extent by the many complex interactions between 5-HT neurons and other neuronal phenotypes, 5-HT receptor heterogeneity, and the conflicting results of some behavioral experiments in animals conducted to date. Through the combined use of modern molecular biology, transgenic animal models, and other more traditional research methods such as medicinal chemistry and classical pharmacology, a clearer picture of the role of serotonin and its receptor subtypes in mnemonic processes is beginning to emerge, however. Considerable data now support the argument that selective ligands at specific 5-HT receptor subtypes can serve as therapeutic agents designed to enhance cognitive function in psychiatric disorders such as schizophrenia as well as age-related neurodegenerative illnesses such as Alzheimer's disease. The purpose of this review is to provide a brief overview of these therapeutic targets within the 5-HT system and the pharmacologic approaches (including the most recently developed compounds) designed to enhance memory function.

Original languageEnglish (US)
Pages (from-to)30-38
Number of pages9
JournalBehavioural Brain Research
Volume195
Issue number1
DOIs
StatePublished - Dec 16 2008

Fingerprint

Serotonin Receptors
Serotonin
Cognition
Therapeutics
Psychiatry
Schizophrenia
Alzheimer Disease
Genetically Modified Animals
Pharmaceutical Chemistry
Cognitive Dysfunction
Anxiety Disorders
Neurotransmitter Agents
Dementia
Molecular Biology
Animal Models
Learning
Pharmacology
Depression
Ligands
Phenotype

Keywords

  • Alzheimer's disease
  • Cognition
  • Dementia
  • Memory
  • Schizophrenia
  • Serotonin

ASJC Scopus subject areas

  • Behavioral Neuroscience

Cite this

Cognitive dysfunction in neuropsychiatric disorders : Selected serotonin receptor subtypes as therapeutic targets. / Terry, Alvin V; Buccafusco, Jerry J.; Wilson, Christina A.

In: Behavioural Brain Research, Vol. 195, No. 1, 16.12.2008, p. 30-38.

Research output: Contribution to journalReview article

@article{34a1c5f196564b918f309cd89cccf546,
title = "Cognitive dysfunction in neuropsychiatric disorders: Selected serotonin receptor subtypes as therapeutic targets",
abstract = "The indolamine, serotonin (5-hydroxytryptamine-5-HT) was identified and initially characterized around the middle of the twentieth century and it is now known to participate in multiple physiologic processes in mammalians. As a neurotransmitter, 5-HT is well documented to play a significant role in the pathophysiology and treatment of a variety of psychiatric disorders including anxiety, depression, and schizophrenia. In addition, there is also some evidence to suggest that 5-HT function in the brain may be important (particularly in the behavioral disturbances) in various forms of dementia including Alzheimer's disease. While 5-HT is undoubtedly involved in cognitive function, its role in specific domains of cognition (attention, learning, and memory, etc.) is poorly understood. This understanding has been impeded to some extent by the many complex interactions between 5-HT neurons and other neuronal phenotypes, 5-HT receptor heterogeneity, and the conflicting results of some behavioral experiments in animals conducted to date. Through the combined use of modern molecular biology, transgenic animal models, and other more traditional research methods such as medicinal chemistry and classical pharmacology, a clearer picture of the role of serotonin and its receptor subtypes in mnemonic processes is beginning to emerge, however. Considerable data now support the argument that selective ligands at specific 5-HT receptor subtypes can serve as therapeutic agents designed to enhance cognitive function in psychiatric disorders such as schizophrenia as well as age-related neurodegenerative illnesses such as Alzheimer's disease. The purpose of this review is to provide a brief overview of these therapeutic targets within the 5-HT system and the pharmacologic approaches (including the most recently developed compounds) designed to enhance memory function.",
keywords = "Alzheimer's disease, Cognition, Dementia, Memory, Schizophrenia, Serotonin",
author = "Terry, {Alvin V} and Buccafusco, {Jerry J.} and Wilson, {Christina A}",
year = "2008",
month = "12",
day = "16",
doi = "10.1016/j.bbr.2007.12.006",
language = "English (US)",
volume = "195",
pages = "30--38",
journal = "Behavioural Brain Research",
issn = "0166-4328",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Cognitive dysfunction in neuropsychiatric disorders

T2 - Selected serotonin receptor subtypes as therapeutic targets

AU - Terry, Alvin V

AU - Buccafusco, Jerry J.

AU - Wilson, Christina A

PY - 2008/12/16

Y1 - 2008/12/16

N2 - The indolamine, serotonin (5-hydroxytryptamine-5-HT) was identified and initially characterized around the middle of the twentieth century and it is now known to participate in multiple physiologic processes in mammalians. As a neurotransmitter, 5-HT is well documented to play a significant role in the pathophysiology and treatment of a variety of psychiatric disorders including anxiety, depression, and schizophrenia. In addition, there is also some evidence to suggest that 5-HT function in the brain may be important (particularly in the behavioral disturbances) in various forms of dementia including Alzheimer's disease. While 5-HT is undoubtedly involved in cognitive function, its role in specific domains of cognition (attention, learning, and memory, etc.) is poorly understood. This understanding has been impeded to some extent by the many complex interactions between 5-HT neurons and other neuronal phenotypes, 5-HT receptor heterogeneity, and the conflicting results of some behavioral experiments in animals conducted to date. Through the combined use of modern molecular biology, transgenic animal models, and other more traditional research methods such as medicinal chemistry and classical pharmacology, a clearer picture of the role of serotonin and its receptor subtypes in mnemonic processes is beginning to emerge, however. Considerable data now support the argument that selective ligands at specific 5-HT receptor subtypes can serve as therapeutic agents designed to enhance cognitive function in psychiatric disorders such as schizophrenia as well as age-related neurodegenerative illnesses such as Alzheimer's disease. The purpose of this review is to provide a brief overview of these therapeutic targets within the 5-HT system and the pharmacologic approaches (including the most recently developed compounds) designed to enhance memory function.

AB - The indolamine, serotonin (5-hydroxytryptamine-5-HT) was identified and initially characterized around the middle of the twentieth century and it is now known to participate in multiple physiologic processes in mammalians. As a neurotransmitter, 5-HT is well documented to play a significant role in the pathophysiology and treatment of a variety of psychiatric disorders including anxiety, depression, and schizophrenia. In addition, there is also some evidence to suggest that 5-HT function in the brain may be important (particularly in the behavioral disturbances) in various forms of dementia including Alzheimer's disease. While 5-HT is undoubtedly involved in cognitive function, its role in specific domains of cognition (attention, learning, and memory, etc.) is poorly understood. This understanding has been impeded to some extent by the many complex interactions between 5-HT neurons and other neuronal phenotypes, 5-HT receptor heterogeneity, and the conflicting results of some behavioral experiments in animals conducted to date. Through the combined use of modern molecular biology, transgenic animal models, and other more traditional research methods such as medicinal chemistry and classical pharmacology, a clearer picture of the role of serotonin and its receptor subtypes in mnemonic processes is beginning to emerge, however. Considerable data now support the argument that selective ligands at specific 5-HT receptor subtypes can serve as therapeutic agents designed to enhance cognitive function in psychiatric disorders such as schizophrenia as well as age-related neurodegenerative illnesses such as Alzheimer's disease. The purpose of this review is to provide a brief overview of these therapeutic targets within the 5-HT system and the pharmacologic approaches (including the most recently developed compounds) designed to enhance memory function.

KW - Alzheimer's disease

KW - Cognition

KW - Dementia

KW - Memory

KW - Schizophrenia

KW - Serotonin

UR - http://www.scopus.com/inward/record.url?scp=53149107135&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53149107135&partnerID=8YFLogxK

U2 - 10.1016/j.bbr.2007.12.006

DO - 10.1016/j.bbr.2007.12.006

M3 - Review article

VL - 195

SP - 30

EP - 38

JO - Behavioural Brain Research

JF - Behavioural Brain Research

SN - 0166-4328

IS - 1

ER -